MX2017013310A - Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico. - Google Patents

Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico.

Info

Publication number
MX2017013310A
MX2017013310A MX2017013310A MX2017013310A MX2017013310A MX 2017013310 A MX2017013310 A MX 2017013310A MX 2017013310 A MX2017013310 A MX 2017013310A MX 2017013310 A MX2017013310 A MX 2017013310A MX 2017013310 A MX2017013310 A MX 2017013310A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
medical use
isoindole derivative
derivative
Prior art date
Application number
MX2017013310A
Other languages
English (en)
Inventor
Dong Qing
Tu Wangyang
Zhang Haitang
Xu Guoji
Chi Jiangtao
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017013310A publication Critical patent/MX2017013310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se relaciona con un derivado de imidazol-isoindol, un método de preparación de los mismos y un uso médico de los mismos. En particular, la presente invención se relaciona con el derivado de imidazol-isoindol como se muestra en la fórmula (I), un método de preparación y la composición farmacéutica que contiene el derivado, y un uso del mismo para tratar enfermedades con características patológicas de los trayectos metabólicos de triptófano mediados por IDO. Las enfermedades comprenden cánceres, enfermedad de Alzheimer, enfermedades autoinmunitarias, depresión, trastornos de ansiedad, cataratas, trastornos psicológicos y SIDA, en donde los sustituyentes en la fórmula (I) son los mismos que aquellos definidos en la descripción. (ver Fórmula).
MX2017013310A 2015-04-21 2016-04-12 Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico. MX2017013310A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510192491 2015-04-21
CN201511019241 2015-12-30
PCT/CN2016/079054 WO2016169421A1 (zh) 2015-04-21 2016-04-12 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2017013310A true MX2017013310A (es) 2018-02-26

Family

ID=57142879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013310A MX2017013310A (es) 2015-04-21 2016-04-12 Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico.

Country Status (11)

Country Link
US (1) US10899764B2 (es)
EP (1) EP3287461B1 (es)
JP (1) JP6801159B2 (es)
KR (1) KR20170139064A (es)
CN (1) CN106715440B (es)
AU (1) AU2016250976B2 (es)
BR (1) BR112017020824A2 (es)
CA (1) CA2981998A1 (es)
MX (1) MX2017013310A (es)
RU (1) RU2717577C2 (es)
WO (1) WO2016169421A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10800780B2 (en) 2015-12-24 2020-10-13 Genentech, Inc. TDO2 Inhibitors
CN108778332B (zh) * 2016-10-21 2019-10-18 苏州盛迪亚生物医药有限公司 Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
CN108884099B (zh) * 2016-10-21 2021-10-08 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
WO2019005559A1 (en) * 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
EP3645537A1 (en) * 2017-06-28 2020-05-06 Genentech, Inc. Tdo2 and ido1 inhibitors
TW201904972A (zh) * 2017-06-30 2019-02-01 大陸商江蘇恆瑞醫藥股份有限公司 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法
WO2019011287A1 (zh) * 2017-07-13 2019-01-17 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物的制备方法
TW201910336A (zh) * 2017-08-08 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種咪唑并異吲哚類衍生物的製備方法
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
CN110041334B (zh) * 2018-01-15 2020-10-20 江苏恒瑞医药股份有限公司 一种氨基苯酚类化合物的制备方法
CN110664812B (zh) * 2018-07-02 2023-04-07 江苏恒瑞医药股份有限公司 一种包含咪唑并异吲哚类衍生物的药物组合物
WO2020063618A1 (zh) * 2018-09-27 2020-04-02 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
JP2024510949A (ja) 2021-03-05 2024-03-12 ウニヴェルシタット・バーゼル Ｅｂｖ関連疾患又は状態の治療用組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US8008281B2 (en) 2003-03-27 2011-08-30 Lankenau Institute For Medical Research Methods for the treatment of cancer
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
NO2694640T3 (es) * 2011-04-15 2018-03-17
US20130079485A1 (en) 2011-09-22 2013-03-28 Prc-Desoto International, Inc. Sulfur-containing polyureas and methods of use
JP6062948B2 (ja) 2011-10-05 2017-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｖ１ａアンタゴニストとしてのシクロヘキシル−４Ｈ，６Ｈ−５−オキサ−２，３，１０ｂ−トリアザ−ベンゾ［ｅ］アズレン
CN103087050A (zh) 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
WO2014015088A1 (en) 2012-07-19 2014-01-23 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2014049133A1 (en) 2012-09-28 2014-04-03 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014193647A2 (en) 2013-05-26 2014-12-04 Calitor Sciences, Llc Alkenyl compounds and methods of use
WO2016131380A1 (en) * 2015-02-16 2016-08-25 Shanghai De Novo Pharmatech Co.,Ltd. Fused-ring compounds, pharmaceutical composition and uses thereof
WO2016165613A1 (en) * 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as ido and tdo inhibitors
US10800780B2 (en) * 2015-12-24 2020-10-13 Genentech, Inc. TDO2 Inhibitors

Also Published As

Publication number Publication date
EP3287461B1 (en) 2020-03-18
BR112017020824A2 (pt) 2018-07-03
CA2981998A1 (en) 2016-10-27
US20180118750A1 (en) 2018-05-03
EP3287461A4 (en) 2018-11-14
CN106715440B (zh) 2019-02-22
US10899764B2 (en) 2021-01-26
CN106715440A (zh) 2017-05-24
RU2717577C2 (ru) 2020-03-24
JP6801159B2 (ja) 2020-12-16
WO2016169421A1 (zh) 2016-10-27
AU2016250976A1 (en) 2017-10-26
EP3287461A1 (en) 2018-02-28
JP2018513145A (ja) 2018-05-24
AU2016250976B2 (en) 2020-02-27
KR20170139064A (ko) 2017-12-18
RU2017136715A3 (es) 2019-09-30
RU2017136715A (ru) 2019-05-21

Similar Documents

Publication Publication Date Title
MX2017013310A (es) Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2016004030A (es) Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
MX2021009673A (es) Moduladores de ror-gamma.
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201691940A1 (ru) Новые соединения
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MD4575C1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MX370487B (es) Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
MY184292A (en) Substituted aminopyrimidine compounds and methods of use
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
EA201700042A1 (ru) Соединения имидазопиридазина
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
PH12017500032A1 (en) Improved a� protofibril binding antibodies
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP3285771A4 (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
WO2014141169A3 (en) Novel anti-neurodegenerative natural compounds isolated from alpiniae oxyphyllae fructus and total synthesis theirof

Legal Events

Date Code Title Description
FG Grant or registration